Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19511526 | 0.87 | HPGD (0.52) | POLBGAACYP3A4HPGDKDM4E | |
| SCHEMBL11506306 | 0.87 | PTPN1 (0.41) | POLBGAACYP3A4HPGDKDM4E | |
| SCHEMBL11505649 | 0.84 | GAA (0.48) | POLBGAACYP3A4HPGDKDM4E | |
| SCHEMBL643051 | 0.84 | LMNA (0.50) | POLBGAAHPGDKDM4ECA12 | |
| SCHEMBL642229 | 0.79 | KDM4E (0.43) | POLBGAACYP3A4HPGDKDM4E | |
| SCHEMBL643761 | 0.79 | POLB (0.49) | POLBGAACYP3A4HPGDKDM4E | |
| SCHEMBL7828001 | 0.76 | CYP3A4 (0.50) | POLBCYP3A4PTPN1TSHRALDH1A1 | |
| SCHEMBL643290 | 0.76 | LMNA (0.56) | POLBGAACYP3A4HPGDKDM4E | |
| SCHEMBL2430731 | 0.76 | LMNA (0.54) | POLBGAACYP3A4KDM4ECA12 | |
| SCHEMBL2770358 | 0.75 | KDM4E (0.55) | GAACYP3A4KDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365501-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES, COMPRISING SAME | CNG BIO CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365501-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES, COMPRISING SAME | CNG BIO CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365501-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES, COMPRISING SAME | CNG BIO CO., LTD. (KR) | 2023-11-16 | — | — | US | disclosed |
| EP-4223742-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE, AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME | CNG Bio Co., Ltd. (KR) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022065823-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE, AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME | 씨엔지바이오 주식회사 | 2022-03-31 | — | — | WO | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2463283-B1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | PFIZER PROD INC (US) | 2014-06-11 | — | — | EP | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2010520-B1 | HETEROBICYCLIC AMIDES FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PROD INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2463283-A1 | Fused phenyl Amido heterocyclic compounds for the prevention and treatment of glucokinase-mediated diseases | Pfizer Products Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7842713-B2 | Fused phenyl amido heterocyclic compounds | PFIZER INC (US) | 2010-11-30 | — | — | US | disclosed |
| EP-2010520-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | Pfizer Products Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | PFIZER INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007122482-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF GLUCOKINASE-MEDIATED DISEASES | PFIZER PRODUCTS INC. (US) | 2007-11-01 | — | — | WO | disclosed |
| US-4143055-A | ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS | GRUPPO LEPETIT S.P.A. (IT) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365501-A1 | 4-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES, COMPRISING SAME | NGF, BDNF, NTRK2 | POLB 3675/4885GAA 2999/4885CYP3A4 4224/4885 |
| US-20080280875-A1 | FUSED PHENYL AMIDO HETEROCYCLIC COMPOUNDS | GCK, GCKR, HK1 | POLB 4200/4885GAA 139/4885CYP3A4 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.